A READING ROOM FOR GLP-1 EVIDENCE
Read the studies, question the claims and understand where provider documentation ends.
START READING
READING GUIDE
Approval status, clinical trial results, pharmacy claims and individualized medical need answer different questions. Here is how to read them without assuming either equivalence or inequivalence.
READING GUIDE
NIDDK frames ongoing weight-management care around response, tolerability and changing circumstances. Public documents from six GLP-1 services show why messaging, refills, laboratory testing and billing should be examined separately.
READING GUIDE
Before accepting a weight-loss percentage or a promise of better tolerability, check who was studied, what they received, what it was compared with—and whether the evidence actually concerns the service being sold.
PROVIDER DIRECTORY
PROVIDER FILE
Washington clinic advertising compounded GLP-1 programs, statewide telehealth, pharmacy dispensing and body-scan support.
Look closer: Clarify exact formulations, full pricing, telehealth-network roles, financing identity and cancellation terms before enrollment.
PROVIDER FILE
Employer-focused access to compounded GLP-1 programs through outside clinical practices and pharmacies.
Look closer: Confirm product identity, state and age eligibility, written charges, follow-up duties and both cancellation deadlines.
PROVIDER FILE
Multiservice medical practice advertising GLP-1 injections, eligibility screening, clinical monitoring and lifestyle support.
Look closer: Confirm the medication, dispensing pharmacy, GLP-1 price, state availability and written follow-up and cancellation terms.
PROVIDER FILE
Online clinical review with compounded GLP-1/B12 offerings, affiliated pharmacy dispensing and direct-to-patient shipping.
Look closer: Clarify consultation fees, microdose state limits, renewal terms, pharmacy identity and delivery-problem procedures.
PROVIDER FILE
Self-pay GLP-1 telehealth membership connecting adults with OpenLoop clinical practices and independent pharmacies.
Look closer: Clarify conflicting cancellation deadlines, bundled commitments, dispensing pharmacy and evidence behind outcome claims.
PROVIDER FILE
One Medical offers clinical GLP-1 evaluation; Amazon Pharmacy separately reviews and dispenses prescriptions.
Look closer: Confirm product-specific prices, state access, laboratory requirements and responsibility for ongoing monitoring.
A READING ROOM FOR GLP-1 EVIDENCE
Use source-linked reporting to prepare better questions. A review can explain the published offer; a healthcare professional must evaluate your individual treatment options.
How we research →
Double-blind randomized trial of 1,961 adults with obesity or overweight and a weight-related condition, without diabetes. Both groups received lifestyle intervention. The semaglutide study arm used a weekly subcutaneous injection; the dose identifies the trial arm, not instructions for use.
Gastrointestinal events led to discontinuation in 4.5% of the semaglutide group and 0.8% of the placebo group. Funded by Novo Nordisk. These averages are not individual predictions or outcomes measured for a reviewed provider or compounded product.
Read the original study ↗| Study group | Mean weight change (%) | Stopped for GI events (%) |
|---|---|---|
| Semaglutide 2.4 mg | -14.9 | 4.5 |
| Placebo | -2.4 | 0.8 |
